Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
2018 |
| gptkbp:ATCCode |
L04AC15
|
| gptkbp:brand |
gptkb:tildrakizumab
|
| gptkbp:form |
solution for injection
|
| gptkbp:frequency |
every 12 weeks after initial doses
|
| gptkbp:halfLife |
20-28 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ilumya
|
| gptkbp:indication |
moderate to severe plaque psoriasis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
interleukin-23 p19 subunit
|
| gptkbp:manufacturer |
gptkb:Sun_Pharma
|
| gptkbp:mechanismOfAction |
IL-23 inhibitor
|
| gptkbp:pregnancyCategory |
Not assigned (consult physician)
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
diarrhea
injection site reactions upper respiratory tract infection |
| gptkbp:usedFor |
plaque psoriasis
|
| gptkbp:bfsParent |
gptkb:Sun_Pharma
|
| gptkbp:bfsLayer |
6
|